These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35184005)

  • 41. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
    Liguori C; Manfredi N; Renna R; Izzi F; Pagliuca M; Pagliuca F; Mercuri NB; Fabio P
    Epileptic Disord; 2020 Jun; 22(3):309-316. PubMed ID: 32540833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence.
    Russo A; Pruccoli J; Cesaroni CA; Belotti LMB; Zenesini C; Bonanni P; Boni A; Cesaroni E; Coppola G; Cordelli DM; Danieli A; Mancardi MM; Marchese F; Matricardi S; Messana T; Nocera GM; Operto FF; Pellino G; Reina F; Vanadia F; Verrotti A; Striano P
    Seizure; 2022 Nov; 102():120-124. PubMed ID: 36223675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe.
    Steinhoff BJ; Christensen J; Doherty CP; Majoie M; De Backer M; Hellot S; Leunikava I; Leach JP
    Epilepsy Res; 2020 Sep; 165():106329. PubMed ID: 32623096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
    Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K
    Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Brivaracetam in children with epilepsy.
    Ferragut Ferretjans F; Soto Insuga V; Bernardino Cuesta B; Cantarín Extremera V; Duat Rodriguez A; Legido MJ; González Alguacil E; Furones García M; Gutiérrez Solana L; Moreno Cantero T; Ruiz Falcó ML; García Peñas JJ
    Epilepsy Res; 2021 Nov; 177():106757. PubMed ID: 34530305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
    Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
    BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis.
    Lee SK; Heo K; Kim SE; Lee SA; Elmoufti S; Laloyaux C; Hur B
    Adv Ther; 2021 Jul; 38(7):4082-4099. PubMed ID: 34155568
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis.
    Lattanzi S; De Maria G; Rosati E; Didato G; Chiesa V; Ranzato F; Canafoglia L; Cesnik E; Anzellotti F; Meletti S; Pauletto G; Nilo A; Bartolini E; Marino D; Tartara E; Luisi C; Bonanni P; Marrelli A; Stokelj D; Dainese F
    Epilepsia; 2021 Jan; 62(1):e1-e6. PubMed ID: 33314118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies.
    Brodie MJ; Whitesides J; Schiemann J; D'Souza J; Johnson ME
    Epilepsy Res; 2016 Nov; 127():114-118. PubMed ID: 27589414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
    Brandt C; Klein P; Badalamenti V; Gasalla T; Whitesides J
    Epilepsy Behav; 2020 Feb; 103(Pt A):106864. PubMed ID: 31937513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A real-world comparison among third-generation antiseizure medications: Results from the COMPARE study.
    Roberti R; Di Gennaro G; Anzellotti F; Arnaldi D; Belcastro V; Beretta S; Boero G; Bonanni P; Canafoglia L; D'Aniello A; Dainese F; De Caro C; Di Gennaro G; Di Giacomo R; DiFrancesco JC; Dono F; Falcicchio G; Ferlazzo E; Foschi N; Franciotta S; Gambardella A; Giordano A; Iannone LF; Labate A; La Neve A; Lattanzi S; Leggio U; Liguori C; Maschio M; Nilo A; Operto FF; Pascarella A; Pauletto G; Renna R; Strigaro G; ; Russo E
    Epilepsia; 2024 Feb; 65(2):456-472. PubMed ID: 38052481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: A meta-analysis and indirect comparison.
    Zhang L; Li S; Li H; Zou X
    Seizure; 2016 Jul; 39():28-33. PubMed ID: 27236448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjunctive Brivaracetam in Indian Patients with Uncontrolled Focal Epilepsy: Results from a Pooled Analysis of Two Double-Blind, Randomized, Placebo-Controlled Trials.
    Srinivasa R; Sinha S; Parthasarthy S; Kothari S; Baviskar R; Jayalakshmi S; Sharma B; Garg RK; Desai J; Yardi N; Salvadeeswaran MS; Ravat S; Das M; Gursahani R; Suresh S; Rasal A; Elmoufti S
    Neurol India; 2020; 68(6):1400-1408. PubMed ID: 33342876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials.
    Moseley B; Bourikas D; Dimova S; Elmoufti S; Borghs S
    Adv Ther; 2024 Apr; 41(4):1746-1758. PubMed ID: 38356105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.
    Farkas MK; Kang H; Fogarasi A; Bozorg A; James GD; Krauwinkel W; Morita D; Will E; Elshoff JP
    Epilepsia; 2022 Apr; 63(4):855-864. PubMed ID: 35196395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time course of drug-related treatment-emergent adverse side effects of brivaracetam.
    Meador KJ; Laloyaux C; Elmoufti S; Gasalla T; Fishman J; Martin MS; Klein P
    Epilepsy Behav; 2020 Oct; 111():107212. PubMed ID: 32544700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and tolerability of adjunctive brivaracetam for the treatment of adult epilepsy: An Australian multi-center retrospective real-world observational cohort study.
    Halliday AJ; Vogrin S; Ignatiadis S; Gillinder L; Jones D; Kiley M; Kwan P; Seneviratne U; Somerville E; Whitham E;
    Epilepsy Behav; 2023 Aug; 145():109287. PubMed ID: 37336131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.